Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Prelude Therapeutics (PRLD) EBIAT (2024 - 2026)

Prelude Therapeutics' EBIAT history spans 3 years, with the latest figure at -$10.4 million for Q1 2026.

  • On a quarterly basis, EBIAT rose 67.63% to -$10.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$77.8 million, a 39.14% increase, with the full-year FY2025 number at -$99.5 million, up 21.76% from a year prior.
  • EBIAT hit -$10.4 million in Q1 2026 for Prelude Therapeutics, up from -$16.5 million in the prior quarter.
  • Over the last five years, EBIAT for PRLD hit a ceiling of -$10.4 million in Q1 2026 and a floor of -$34.7 million in Q2 2024.
  • Historically, EBIAT has averaged -$26.3 million across 3 years, with a median of -$31.2 million in 2025.
  • Biggest five-year swings in EBIAT: decreased 2.08% in 2025 and later surged 67.63% in 2026.
  • Tracing PRLD's EBIAT over 3 years: stood at -$28.7 million in 2024, then surged by 42.72% to -$16.5 million in 2025, then surged by 36.9% to -$10.4 million in 2026.
  • Business Quant data shows EBIAT for PRLD at -$10.4 million in Q1 2026, -$16.5 million in Q4 2025, and -$19.7 million in Q3 2025.